E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Bronchial Asthma (persistent) |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this clinical trial is to assess the efficacy of Teikoku Tulobuterol Tape (TTT) compared to placebo, in management of asthma symptoms in a population of adults with persistent bronchial asthma. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1.Diagnosis of persistent bronchial asthma for at least 1 year prior to Visit 1, as defined by the Global Initiative for Asthma (GINA 2004); 2. Spirometric FEV1 on baseline visit should be between ≥ 60% and ≤ 90% of predicted normal FEV1 for age, sex, race, and height (without medication in prior 6 hours) at Visit 2; 3.Treatment with inhaled or nasal corticosteroids and/or immunotherapy that has been “dose stable” for ≥ 30 days prior to Visit 1 and will continue throughout the study; 4.Improvement in spirometric FEV1 ≥ 12% and at least 200 mL from that day’s unmedicated FEV1 within 15-20 minutes following inhalation of two actuations of albuterol sulfate (total of 200 mcg) beta2-agonist at Visit 2; 5.Female subjects must be postmenopausal (defined as one year without menses), physically incapable of becoming pregnant, or using an acceptable birth control method. Acceptable methods of birth control include hormonal contraceptives or double-barrier methods (condom or diaphragm with spermicidal agent or IUD). If practicing an acceptable method of birth control, the subject must have confirmation of a negative urine pregnancy test at Visit 3; 6.No evidence of any chronic condition that might affect respiratory function; 7.Subject understands the procedures and has signed an informed consent form.
|
|
E.4 | Principal exclusion criteria |
1.Diagnosis of other airway obstruction, bronchopulmonary aspergillosis, or any form of allergic alveolitis; 2. Initiation of treatment with systemic, nasal and/or inhaled corticosteroids or immunotherapy during study; 3. Exacerbation of asthma during the screening period defined by 20% decrease in patient`s morning or evening PEF for three consecutive days on patient`s Daily Diary as determined by the investigator at the clinic visit; 4. Treatment with oral beta2-agonists, long acting beta2-agonists, theophylline, leukotriene antagonists, cromolyn sodium, nedocromil sodium, or ipratropium bromide after Visit 1; 5. Treatment with beta-blockers (including eye drops), or non-prescription asthma medication, or use of any prescription drug to which albuterol sulfate administration is contraindicated after Visit1; 6. Treatment with systemic (oral, IV, IM or rectal) corticosteroids within 30 days of Visit1; 7. Treatment with long-acting antihistamines within 10 days of Visit 2; 8. Active pulmonary disorders (other than asthma or allergies) or a respiratory infection within 3 weeks of Visit 1 or between Visit 1 and 3; 9. History of the exacerbation of asthma requiring the use of oral or parenteral corticosteroids within 3 months prior to Visit 1; 10. History of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest or hypoxic seizures at anytime prior to Visit 1; 11.Clinically significant abnormalities of serum chemistry or hematology at Visit 2; 12.History of (within the previous 10 years) any malignant or pre-malignant condition. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- change between baseline and Week 2 in the 7-day average morning peak expiratory flow (AM PEF) |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Information not present in EudraCT |
E.6.4 | Safety | Information not present in EudraCT |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 9 |